| Year |
Citation |
Score |
| 2008 |
Beliakoff J, Lee J, Ueno H, Aiyer A, Weissman IL, Barsh GS, Cardiff RD, Sun Z. The PIAS-like protein Zimp10 is essential for embryonic viability and proper vascular development. Molecular and Cellular Biology. 28: 282-92. PMID 17967885 DOI: 10.1128/Mcb.00771-07 |
0.385 |
|
| 2007 |
Lee J, Beliakoff J, Sun Z. The novel PIAS-like protein hZimp10 is a transcriptional co-activator of the p53 tumor suppressor. Nucleic Acids Research. 35: 4523-34. PMID 17584785 DOI: 10.1093/Nar/Gkm476 |
0.437 |
|
| 2007 |
Li TH, Zhao H, Peng Y, Beliakoff J, Brooks JD, Sun Z. A promoting role of androgen receptor in androgen-sensitive and -insensitive prostate cancer cells. Nucleic Acids Research. 35: 2767-76. PMID 17426117 DOI: 10.1093/Nar/Gkm198 |
0.336 |
|
| 2006 |
Beliakoff J, Sun Z. Zimp7 and Zimp10, two novel PIAS-like proteins, function as androgen receptor coregulators Nuclear Receptor Signaling. 4. PMID 16862223 DOI: 10.1621/Nrs.04017 |
0.453 |
|
| 2006 |
Li X, Thyssen G, Beliakoff J, Sun Z. The novel PIAS-like protein hZimp10 enhances Smad transcriptional activity. The Journal of Biological Chemistry. 281: 23748-56. PMID 16777850 DOI: 10.1074/Jbc.M508365200 |
0.371 |
|
| 2005 |
Jeffy BD, Hockings JK, Kemp MQ, Morgan SS, Hager JA, Beliakoff J, Whitesell LJ, Bowden GT, Romagnolo DF. An estrogen receptor-alpha/p300 complex activates the BRCA-1 promoter at an AP-1 site that binds Jun/Fos transcription factors: repressive effects of p53 on BRCA-1 transcription. Neoplasia (New York, N.Y.). 7: 873-82. PMID 16229810 DOI: 10.1593/Neo.05256 |
0.519 |
|
| 2005 |
Huang CY, Beliakoff J, Li X, Lee J, Li X, Sharma M, Lim B, Sun Z. hZimp7, a novel PIAS-like protein, enhances androgen receptor-mediated transcription and interacts with SWI/SNF-like BAF complexes. Molecular Endocrinology (Baltimore, Md.). 19: 2915-29. PMID 16051670 DOI: 10.1210/Me.2005-0097 |
0.424 |
|
| 2005 |
Bagatell R, Beliakoff J, David CL, Marron MT, Whitesell L. Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin International Journal of Cancer. 113: 179-188. PMID 15455381 DOI: 10.1002/Ijc.20611 |
0.521 |
|
| 2004 |
Beliakoff J, Whitesell L. Hsp90: an emerging target for breast cancer therapy. Anti-Cancer Drugs. 15: 651-662. PMID 15269596 DOI: 10.1097/01.Cad.0000136876.11928.Be |
0.584 |
|
| 2004 |
Beliakoff J, Bagatell R, Paine-Murrieta G, Taylor CW, Lykkesfeldt AE, Whitesell L. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 4961-71. PMID 14581371 |
0.587 |
|
| Show low-probability matches. |